Authors: Payam Sasanejad, Leila Afshar Hezarkhani, Shahram Arsang-Jang, Georgios Tsivgoulis, Abdoreza Ghoreishi, Barlinn Kristian, Jan Rahmig, Mehdi Farhoudi, Elyar Sadeghi Hokmabadi, Afshin Borhani-Haghighi, Payam Sariaslani, Athena Sharifi-Razavi, Kavian Ghandehari, Alireza Khosravi, Craig J. Smith, Yongchai Nilanont, Yama Akbari, Thanh N. Nguyen, Anna Bersano, Nawaf Yassi, Takeshi Yoshimoto, Simona Lattanzi, Animesh Gupta, Ramin Zand, Shahram Rafie, Seyede Pourandokht Mousavian, Mohammad Reza Shahsavaripour, Shahram Amini, Saltanat Kamenova, Aida Kondybayeva, Murat Zhanuzakov, Elizabeth Macri, Christa O'Hana S. Nobleza, Sean Ruland, Anna M. Cervantes-Arslanian, Masoom Desai, Annemarei Ranta, Amir Moghadam Ahmadi, Mahtab Rostamihosseinkhani, Razieh Foroughi, Etrat Hooshmandi, Fahimeh Haji Akhoundi, Ashfaq Shuaib, David S Liebeskind, James E. Siegler, Jose G. Romano, Stephan A. Mayer, Reza Bavarsad Shahripour, Babak Zamani, Amadene Woolsey, Yasaman Fazli, Khazaei Mojtaba, Christian F Isaac, José Biller, Mario Di Napoli, M. Reza Azarpazhooh
Venue: Journal of Stroke and Cerebrovascular Diseases
Type: Publication
Abstract: BackgroundThere is little information regarding the safety of intravenous tissue plasminogen activator (IV-tPA) in patients with stroke and COVID-19.MethodsThis multicenter study included consecutive stroke patients with and without COVID-19 treated with IV-tPA between February 18, 2019, to December 31, 2020, at 9 centers participating in the CASCADE initiative. Clinical outcomes included modified Rankin Scale (mRS) at hospital discharge, in-hospital mortality, the rate of hemorrhagic transformation. Using Bayesian multiple regression and after...
(read more)
Topics: 
Internal medicine
Cardiology
Intensive care medicine
Loading (it may take a couple of seconds)...
Loading (it may take a couple of seconds)...